{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T16:19:32Z","timestamp":1787933972386,"version":"build-2784847793"},"reference-count":34,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T00:00:00Z","timestamp":1709164800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.diagmicrobio.2024.116235","type":"journal-article","created":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T01:25:59Z","timestamp":1709169959000},"page":"116235","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["In vitro activity of ceftazidime-avibactam against gram-negative bacteria in patients with bacteremia and skin and soft-tissue infections in Colombia 2019\u20132021"],"prefix":"10.1016","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2506-2000","authenticated-orcid":false,"given":"Elkin Vladimir","family":"Lemos-Luengas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sixta","family":"Renter\u00eda-Valoyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana Marcela Almario","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinthya Katherine Galindo","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Guerr\u00f3n-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3297-0012","authenticated-orcid":false,"given":"Jorge Andres","family":"Ramos-Castaneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.diagmicrobio.2024.116235_bib0001","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.3390\/pathogens10101310","article-title":"Bacterial antibiotic resistance: the most critical pathogens","volume":"10","author":"Mancuso","year":"2021","journal-title":"Pathogens"},{"issue":"10325","key":"10.1016\/j.diagmicrobio.2024.116235_bib0002","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Murray","year":"2022","journal-title":"Lancet North Am Ed"},{"key":"10.1016\/j.diagmicrobio.2024.116235_bib0003","series-title":"Antimicrobial resistance in the EU\/EEA (EARS-Net) Annual Epidemiological Report 2019","first-page":"28","year":"2020"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2024.116235_bib0004","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S1473-3099(18)30605-4","article-title":"Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis","volume":"19","author":"Cassini","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"SUPPL.1","key":"10.1016\/j.diagmicrobio.2024.116235_bib0005","doi-asserted-by":"crossref","first-page":"91","DOI":"10.7705\/biomedica.v34i0.1667","article-title":"Evoluci\u00f3n de la resistencia antimicrobiana de bacilos gram negativos en unidades de cuidados intensivos en Colombia","volume":"34","author":"Hern\u00e1ndez-G\u00f3mez","year":"2013","journal-title":"Biom\u00e9dica"},{"key":"10.1016\/j.diagmicrobio.2024.116235_bib0006","series-title":"Antibiotic resistance threats in the United States","first-page":"1","year":"2019"},{"key":"10.1016\/j.diagmicrobio.2024.116235_bib0007","first-page":"1","volume":"21287","author":"Tamma","year":"2020"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2024.116235_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2023.115945","article-title":"Ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam activities against multidrug-resistant Enterobacterales from United States Medical Centers (2018\u20132022)","volume":"106","author":"Sader","year":"2023","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2024.116235_bib0009","doi-asserted-by":"crossref","first-page":"735","DOI":"10.2147\/IDR.S345574","article-title":"Clinical perspective of antimicrobial resistance in bacteria","volume":"15","author":"Zhu","year":"2022","journal-title":"Infect Drug Resist"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2024.116235_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.bjid.2023.102759","article-title":"Epidemiology and in vitro activity of ceftazidime-avibactam and comparator agents against multidrug-resistant isolates of Enterobacterales and Pseudomonas aeruginosa collected in Latin America as part of the ATLAS surveillance program in 2015\u20122020","volume":"27","author":"Wise","year":"2023","journal-title":"Braz J Infect Dis"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2024.116235_bib0011","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1093\/cid\/ciaa065","article-title":"Languid uptake of ceftazidime-avibactam for carbapenem-resistant gram-negative infections and continued reliance on polymyxins","volume":"72","author":"Satlin","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2024.116235_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106045","article-title":"In vitro activity of ceftazidime-avibactam against gram-negative isolates collected in 18 European countries, 2015\u20132017","volume":"56","author":"Stone","year":"2020","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2024.116235_bib0013","doi-asserted-by":"crossref","first-page":"114835","DOI":"10.1016\/j.diagmicrobio.2019.05.007","article-title":"Longitudinal analysis of the in vitro activity of ceftazidime-avibactam vs. Pseudomonas aeruginosa, 2012\u20132016","volume":"96","author":"Stone","year":"2020","journal-title":"Diagnostic Microbiology and Infectious Disease"},{"key":"10.1016\/j.diagmicrobio.2024.116235_bib0014","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jgar.2022.02.018","article-title":"In vitro activity of ceftazidime\/avibactam against Gram-negative strains in Colombia 2014\u20132018","volume":"29","author":"Lemos-Luengas","year":"2022","journal-title":"J Global Antimicrob Resist"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2024.116235_bib0015","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s40121-023-00762-9","article-title":"The use and effectiveness of ceftazidime\u2013avibactam in real-world clinical practice: EZTEAM study","volume":"12","author":"Soriano","year":"2023","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.diagmicrobio.2024.116235_bib0016","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.2147\/IDR.S209264","article-title":"Optimal management of complicated infections in the pediatric patient: the role and utility of ceftazidime\/avibactam","volume":"13","author":"Bassetti","year":"2020","journal-title":"Infect Drug Resist"},{"issue":"8","key":"10.1016\/j.diagmicrobio.2024.116235_bib0017","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1097\/INF.0000000000002344","article-title":"Use of ceftazidime-avibactam for the treatment of extensively drug-resistant or pan drug-resistant Klebsiella pneumoniae in neonates and children< 5 years of age","volume":"38","author":"Iosifidis","year":"2019","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.diagmicrobio.2024.116235_bib0018","unstructured":"Pfizer. ATLAS (Antimicrobial Testing Leadership and Surveillance) [Internet]. [2023\/11\/10]. Available from: https:\/\/atlas-surveillance.com\/\/#\/login."},{"key":"10.1016\/j.diagmicrobio.2024.116235_bib0019","series-title":"Performance standards for antimicrobial susceptibility testing","year":"2023"},{"key":"10.1016\/j.diagmicrobio.2024.116235_bib0020","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jgar.2023.09.004","article-title":"In vitro activity of ceftazidime-avibactam against Gram-negative strains in Chile 2015\u20132021","volume":"35","author":"Torres-Castillo","year":"2023","journal-title":"J Glob Antimicrob Resist"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2024.116235_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.bjid.2021.101647","article-title":"In vitro activity of ceftazidime-avibactam against enterobacterales and pseudomonas aeruginosa isolates collected in Latin America as part of the ATLAS global surveillance program, 2017\u20132019","volume":"25","author":"Karlowsky","year":"2021","journal-title":"Braz J Infect Dis"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2024.116235_bib0022","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3390\/antibiotics9020062","article-title":"In vitro susceptibility to ceftazidime\/avibactam and comparators in clinical isolates of enterobacterales from five Latin American Countries","volume":"9","author":"Appel","year":"2020","journal-title":"Antibiotics"},{"key":"10.1016\/j.diagmicrobio.2024.116235_bib0023","doi-asserted-by":"crossref","first-page":"e0277","DOI":"10.1590\/0037-8682-0277-2022","article-title":"Fran\u00e7a PHC de. Evaluation of in-vitro susceptibility of \u00df-lactam-resistant gram-negative bacilli to ceftazidime-avibactam and ceftolozane-tazobactam from clinical samples of a general hospital in southern Brazil","volume":"56","author":"Carvalho","year":"2023","journal-title":"Rev Soc Bras Med Trop"},{"key":"10.1016\/j.diagmicrobio.2024.116235_bib0024","first-page":"26","article-title":"In vitro activity of ceftazidime-avibactam against Gram-negative strains in patients with complicated urinary tract infection and complicated intra-abdominal infection in Colombia 2014-2018","author":"Lemos-Luengas","year":"2022","journal-title":"Braz J Infect Dis"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2024.116235_bib0025","doi-asserted-by":"crossref","first-page":"106439","DOI":"10.1016\/j.ijantimicag.2021.106439","article-title":"Activity of ceftazidime\/avibactam, meropenem\/vaborbactam and imipenem\/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals","volume":"58","author":"Castanheira","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2024.116235_bib0026","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jgar.2021.08.010","article-title":"In vitro activity of ceftazidime\/avibactam and comparators against carbapenemase-producing Enterobacterales and pseudomonas aeruginosa isolates collected globally between 2016 and 2018","volume":"27","author":"Kiratisin","year":"2021","journal-title":"J Global Antimicrob Resist"},{"key":"10.1016\/j.diagmicrobio.2024.116235_bib0027","unstructured":"Ministerio de Salud y Protecci\u00f3n Social, Instituto Nacional de Vigilancia de Medicamentos y Alimentos \u2013 INVIMA. Resoluci\u00f3n No. 2019052727 de Noviembre 22 de 2019 [Internet]. 2019 [citado 2023\/11\/10]. Disponible en: https:\/\/www.invima.gov.co\/documents\/20143\/1587207\/INVIMA+2019M+19450-2019052727.pdf."},{"issue":"3","key":"10.1016\/j.diagmicrobio.2024.116235_bib0028","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2024.116235_bib0029","doi-asserted-by":"crossref","unstructured":"Stone GG, Seifert H, Nord CE. In vitro activity of ceftazidime-avibactam against gram-negative isolates collected in 18 European countries, 2015\u20132017. Int J Antimicrob Agents. 106045.","DOI":"10.1016\/j.ijantimicag.2020.106045"},{"issue":"10","key":"10.1016\/j.diagmicrobio.2024.116235_bib0030","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1093\/jac\/dky266","article-title":"In vitro activity of ceftazidime\/avibactam against isolates of Enterobacteriaceae collected in European countries: INFORM global surveillance 2012\u201315","volume":"73","author":"Kazmierczak","year":"2018","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2024.116235_bib0031","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/cid\/ciu444","article-title":"Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America","volume":"59","author":"Stevens","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2024.116235_bib0032","doi-asserted-by":"crossref","first-page":"318","DOI":"10.22354\/in.v23i4.805","article-title":"Gu\u00eda de pr\u00e1ctica cl\u00ednica para el diagn\u00f3stico y manejo de las infecciones de piel y tejidos blandos en Colombia","volume":"23","author":"Valderrama-Beltr\u00e1n","year":"2019","journal-title":"Infectio"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2024.116235_bib0033","doi-asserted-by":"crossref","first-page":"577","DOI":"10.4067\/S0716-10182017000600577","article-title":"Seguridad de las fluoroquinolonas: riesgos habitualmente olvidados para el cl\u00ednico","volume":"34","author":"Gonz\u00e1lez","year":"2017","journal-title":"Revista Chilena de Infectolog\u00eda"},{"key":"10.1016\/j.diagmicrobio.2024.116235_bib0034","series-title":"M100 performance standards for antimicrobial susceptibility testing","year":"2020"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889324000646?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889324000646?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:59:54Z","timestamp":1760003994000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889324000646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S0732889324000646"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2024.116235","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro activity of ceftazidime-avibactam against gram-negative bacteria in patients with bacteremia and skin and soft-tissue infections in Colombia 2019\u20132021","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2024.116235","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"116235"}}